Stage iv pancreatic cancer ajcc v8 Trials in Columbus, United States
Conditions / Stage iv pancreatic cancer ajcc v8 / Columbus, United States
Clinical trials for Stage iv pancreatic cancer ajcc v8 investigate a range of treatment strategies and patient populations.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04548752 | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | ACTIVE_NOT_RECRUITING | — |
| NCT04548752 | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | ACTIVE_NOT_RECRUITING | — |
| NCT04548752 | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | ACTIVE_NOT_RECRUITING | — |
| NCT04548752 | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | ACTIVE_NOT_RECRUITING | — |
| NCT05554367 | Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial | ACTIVE_NOT_RECRUITING | — |
| NCT04548752 | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | ACTIVE_NOT_RECRUITING | — |
| NCT04548752 | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | ACTIVE_NOT_RECRUITING | — |
| NCT05554367 | Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial | ACTIVE_NOT_RECRUITING | — |
| NCT04548752 | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | ACTIVE_NOT_RECRUITING | — |
| NCT04548752 | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | ACTIVE_NOT_RECRUITING | — |